Versant Venture V AIV
SelectiveSan Francisco, CABiotechnology, Healthcare, PharmaceuticalsLast fund filed November 2016
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Versant Venture V AIV Feeder Holdings, L.P. | November 2016 | $5.3M | $5.3M | 7 |
| Versant Venture V AIV, L.P. | November 2016 | $22M | $22M | 32 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kirk Nielsen | Selective | Medical devices, Biotech & pharma, Digital health | 18 | 3 |
Classified sectors of Versant Venture V AIV’s own portfolio companies, based on 55 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Venture Capital | 55 | 858 Therapeutics, AcuFocus, Alexza Pharmaceuticals, Aligos Therapeutics, Allegro Ophthalmics, Alleviant Medical, Alphaeon, Artelon, Audentes Therapeutics, BIRD ROCK BIO, Bright Peak Therapeutics, Ceterix Orthopaedics, CRISPR Therapeutics AG, CVRx, Edwards Lifesciences, Equinox Ophthalmic, Euro Ventures 4, FLUIDIGM, HOLAIRA, Inari Medical, Inception 5, Inception IBD, iVEAcare, Jengu Therapeutics, Kanyos Bio, KINESTRAL TECHNOLOGIES, LENSAR, Lycia Therapeutics, Metavention, Monte Rosa Therapeutics, Monteris Medical US, Moxe Health, NEOVISTA, Neurolens, NEUWAVE MEDICAL, Northern Mosaic, Okami Medical, OneFocus Vision, Oyster Point Pharma, Prelude, Rampart IC, RENNOVIA, Respicardia, RxSight, Santa Ana Bio, SECOND SIGHT MEDICAL PRODUCTS, Sequent Medical, SpyGlass Ophthalmics, TearClear, Tempest Therapeutics, VERACYTE, VI1, ViaLase, Vividion Therapeutics, ZYGA TECHNOLOGY |
| Versant Voyageurs | 37 | 858 Therapeutics, Aligos Therapeutics, Alleviant Medical, Artelon, Audentes Therapeutics, BIRD ROCK BIO, Black Diamond Therapeutics, Bright Peak Therapeutics, Ceterix Orthopaedics, CRISPR Therapeutics AG, CVRx, Euro Ventures 4, HOLAIRA, Inari Medical, Inception 5, Inception IBD, iVEAcare, Jengu Therapeutics, Kanyos Bio, Lycia Therapeutics, Metavention, Monte Rosa Therapeutics, Monteris Medical US, Moxe Health, NEUWAVE MEDICAL, Northern Mosaic, Okami Medical, Oyster Point Pharma, Rampart IC, Respicardia, Santa Ana Bio, Sequent Medical, SpyGlass Ophthalmics, Tempest Therapeutics, VI1, Vividion Therapeutics, ZYGA TECHNOLOGY |
| Bradley Bolzon | Quiet | Biotech & pharma | 10 | 0 |
| Robin Praeger | Quiet | None listed | 0 | 0 |
| Samuel Colella | Quiet | Biotech & pharma, Climate & energy, Manufacturing & industrials | 5 | 0 |
| Thomas Woiwode | Quiet | Biotech & pharma | 13 | 0 |
| William Link | Quiet | Medical devices, Biotech & pharma, Digital health | 16 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Versant Venture V AIV’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Versant Side | 35 | 858 Therapeutics, AcuFocus, Alexza Pharmaceuticals, Allegro Ophthalmics, Alphaeon, BIRD ROCK BIO, Black Diamond Therapeutics, Ceterix Orthopaedics, CRISPR Therapeutics AG, Edwards Lifesciences, Equinox Ophthalmic, FLUIDIGM, Inari Medical, Inception 1, Inception 5, Inception IBD, KINESTRAL TECHNOLOGIES, LENSAR, Monte Rosa Therapeutics, NEOVISTA, Neurolens, Northern Mosaic, Okami Medical, OneFocus Vision, Oyster Point Pharma, Prelude, RENNOVIA, RxSight, SECOND SIGHT MEDICAL PRODUCTS, Sequent Medical, SIGHTLIFE SURGICAL, TearClear, Tempest Therapeutics, VERACYTE, ViaLase |
| Versant Vantage | 19 | 858 Therapeutics, Aligos Therapeutics, Audentes Therapeutics, BIRD ROCK BIO, Black Diamond Therapeutics, Bright Peak Therapeutics, CRISPR Therapeutics AG, Euro Ventures 4, Inception 5, Inception IBD, Jengu Therapeutics, Kanyos Bio, Lycia Therapeutics, Monte Rosa Therapeutics, Northern Mosaic, Oyster Point Pharma, Santa Ana Bio, Tempest Therapeutics, Vividion Therapeutics |
| U.S Venture Partners | 4 | Inari Medical, Okami Medical, Sequent Medical, ViaLase |
| Stack Infrastructure | 3 | Inari Medical, Okami Medical, Sequent Medical |
| Domain Partners | 2 | Sequent Medical, ZYGA TECHNOLOGY |
| Vivo Capital | 2 | Aligos Therapeutics, Kanyos Bio |
| Vivo Innovation | 2 | Aligos Therapeutics, Kanyos Bio |
| 270 Healthcare Growth | 1 | Audentes Therapeutics |
| Amzl | 1 | CRISPR Therapeutics AG |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Caduceus Capital | 1 | Audentes Therapeutics |
| Camber Creek | 1 | Alleviant Medical |
| Lightstone Ventures | 1 | HOLAIRA |
A shared board seat: a company where filings name a Versant Venture V AIV partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.